PedSAP 2021 Book 2 (*Neurology and Psychiatry)*
Release date: September 15, 2021
BCPS test deadline: 11:59 p.m. (Central) on March 15, 2022.
ACPE test deadline: 11:59 p.m. (Central) on September 15, 2024.

Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

PedSAP Target Audience: The target audience for PedSAP 2021 Book 2 (*Neurology and Psychiatry*) is board-certified and advanced-level clinical pharmacists caring for pediatric patients with psychiatric and neurological conditions.

Module I (5.0 CPE): 0217-0000-21-068-H01-P

Chapter: Eating Disorders
Learning Objectives
1. Evaluate methods of screening for eating disorders throughout childhood and the general approach to determining an appropriate level of care.
2. Analyze the role of psychotropic medications in the treatment of anorexia nervosa (AN).
3. Develop a monitoring plan and appropriate recommendations for nutritional and electrolyte supplementation for a pediatric patient with AN.
4. Analyze the role of psychotropic medications in the treatment of bulimia nervosa (BN).
5. Develop a monitoring plan and appropriate recommendations for nutritional and electrolyte supplementation for a pediatric patient with BN.
6. Distinguish between diagnostic and hallmark features of AN, BN, binge-eating disorder, and avoidant/restrictive food intake disorder.

Chapter: Depression
Learning Objectives
1. Detect signs and symptoms of common depressive disorders in youth.
2. Classify clinical sequelae of depression in pediatric or adolescent patients.
3. Design a treatment regimen for a pediatric or adolescent patient with depression that includes nonpharmacologic therapy and antidepressants.
4. Evaluate the risks and warnings associated with antidepressant use in children and adolescents, and demonstrate how to counsel patients and/or caregivers on managing those risks.

Module II (4.0 CPE): 0217-0000-21-069-H01-P

Chapter: Bipolar Disorder
Learning Objectives
1. Evaluate potential risk factors for the development of pediatric bipolar disorder (PBD).
2. Assess a patient for signs and symptoms consistent with PBD.
3. Apply available guidelines to create a treatment plan for a patient with PBD.
4. Assess the place in therapy of pharmacologic and nonpharmacologic treatment options for PBD.
5. Design a comprehensive treatment plan for an individual with PBD that includes comorbid psychiatric disorders.

Chapter: Attention-Deficit/Hyperactivity Disorder
Learning Objectives
1. Assess a patient for signs and symptoms consistent with attention-deficit/hyperactivity disorder (ADHD).
2. Analyze treatment guideline recommendations for ADHD.
3. Distinguish between unique dosage formulations of stimulant treatments for ADHD.
4. Evaluate place for nonstimulant treatment options in therapy for ADHD.
5. Develop a comprehensive treatment plan for a patient with ADHD, taking into consideration commonly comorbid psychiatric conditions.

Module III (4.5 CPE): 0217-0000-21-070-H01-P

Chapter: Epilepsy in Children and Adolescents
Learning Objectives
1. Apply insights from genetics and adherence research to optimize therapy for pediatric patients with epilepsy.
2. Evaluate an antiseizure medication regimen for pediatric patients based on considerations for seizure type, adverse effect profile, and patient quality of life.
3. Design a treatment plan for pediatric patients with medication-refractory epilepsy.
4. Develop a seizure rescue plan for pediatric patients.
5. Assess the impact of a treatment plan on comorbidities and long-term health for pediatric patients with epilepsy.

Chapter: Sleep Disorders
Learning Objectives
1. Distinguish the differences between the various types of sleep disorders common in children and adolescents to determine the safest and most effective clinical management plan.
2. Devise patient-specific goals of therapy for sleep disorders on the basis of the typical developmental sleep patterns and the consequences of sleep disorders in pediatric patients.
3. Assess the risk of development of sleep disorders in children and adolescents.

4. Apply an understanding of the pharmacology and pharmacokinetics of medications used to treat sleep disorders to achieve patient-specific goals of therapy.
5. Develop a complete management plan, including both drug and nondrug recommendations as appropriate, for a given child or adolescent presenting with a sleep disorder.

Module IV (4.5 CPE): 0217-0000-21-071-H01-P

Interactive Case: Posttraumatic Stress Disorder
Learning Objectives
1. Detect potential risk factors, protective factors, symptoms, and consequences of PTSD in a presented patient case.
2. Classify symptoms associated with various trauma/stressor related disorders in children and adolescents.
3. Devise an evidence-based recommendation for prevention of PTSD.
4. Design a treatment plan for a child/adolescent diagnosed with PTSD.

Interactive Case: Headaches
Learning Objectives
1. Distinguish the differences between headaches and migraines, including risk factors, classification, and evaluation.
2. Design an evidence-based plan with appropriate nonpharmacologic and pharmacologic treatment options for acute management of headaches.
3. Design and implement an evidence-based plan with appropriate management for status migrainosus.
4. Design appropriate therapy for a patient with cyclic vomiting syndrome.
5. Analyze novel therapies for pediatric patients with headaches.

Interactive Case: Vaping and Smoking Cessation in Adolescents
Learning Objectives
1. Distinguish the differences between electronic cigarettes (e-cigarettes) and combustible cigarettes, including risks specific to e-cigarette use.
2. Justify appropriate nonpharmacologic and pharmacologic interventions on the basis of relevant patient factors.
3. Develop an evidence-based plan to reach the desired therapeutic outcomes and treatment goals.
4. Design disease- and/or drug-specific monitoring with appropriate time intervals to ensure the safety and optimization of therapeutic plans.